PURPOSE: The goal of this research was to estimate 12-month survival rates for a large sample of elderly veterans after hip fracture with a risk-adjusted model and to compare the results of men to those of women. METHODS: The study design was a retrospective, secondary data analysis of national Veterans Health Administration (VHA) Medicare beneficiaries. The study population was 43,165 veterans with hip fracture first admitted to a Medicare-eligible facility during our specified enrollment period of 1999-2002. Measurement was a Cox proportional hazard model or survival analysis of hip fracture patients with an outcome of death over a 1 year period after discharge controlled by age, gender, and selected Elixhauser comorbidities. RESULTS: The unadjusted, 1 year mortality rates (30 days = 9.7%, 90 days = 17.5%, 180 days = 24%, 365 days = 32.2%) were slightly higher than the adjusted rates (30 days = 8.9%, 90 days = 15.6%, 180 days = 21.8%, 1 year = 29.9%). The mortality odds for women 12 months after hip fracture were 18%, compared with 32% for men. The comorbidity adjustment suggested that the presence of metastatic cancer increased the risk of death by almost 4 times compared with those patients without this diagnosis. Other particularly high-risk conditions included congestive heart failure, renal failure, liver disease, lymphoma, and weight loss, each of which increased the 1 year mortality risk by approximately two-fold. CONCLUSIONS: One in 3 elderly male veterans who sustain a hip fracture dies within 1 year. Our work represents the first large study of hip fractures with a predominantly male sample and confirms that men have a higher mortality risk than women, as reported by previous researchers who used smaller samples that were mostly female. Fracture patients with metastatic cancer, renal failure, lymphoma, weight loss, and liver disease have higher mortality risks. The adverse outcomes associated with hip fracture argue for clinical intervention strategies, such as gait and balance testing, and osteoporosis diagnosis that may prevent fractures in both genders.
PURPOSE: The goal of this research was to estimate 12-month survival rates for a large sample of elderly veterans after hip fracture with a risk-adjusted model and to compare the results of men to those of women. METHODS: The study design was a retrospective, secondary data analysis of national Veterans Health Administration (VHA) Medicare beneficiaries. The study population was 43,165 veterans with hip fracture first admitted to a Medicare-eligible facility during our specified enrollment period of 1999-2002. Measurement was a Cox proportional hazard model or survival analysis of hip fracturepatients with an outcome of death over a 1 year period after discharge controlled by age, gender, and selected Elixhauser comorbidities. RESULTS: The unadjusted, 1 year mortality rates (30 days = 9.7%, 90 days = 17.5%, 180 days = 24%, 365 days = 32.2%) were slightly higher than the adjusted rates (30 days = 8.9%, 90 days = 15.6%, 180 days = 21.8%, 1 year = 29.9%). The mortality odds for women 12 months after hip fracture were 18%, compared with 32% for men. The comorbidity adjustment suggested that the presence of metastatic cancer increased the risk of death by almost 4 times compared with those patients without this diagnosis. Other particularly high-risk conditions included congestive heart failure, renal failure, liver disease, lymphoma, and weight loss, each of which increased the 1 year mortality risk by approximately two-fold. CONCLUSIONS: One in 3 elderly male veterans who sustain a hip fracture dies within 1 year. Our work represents the first large study of hip fractures with a predominantly male sample and confirms that men have a higher mortality risk than women, as reported by previous researchers who used smaller samples that were mostly female. Fracturepatients with metastatic cancer, renal failure, lymphoma, weight loss, and liver disease have higher mortality risks. The adverse outcomes associated with hip fracture argue for clinical intervention strategies, such as gait and balance testing, and osteoporosis diagnosis that may prevent fractures in both genders.
Authors: A Agustí; E Pagès; A Cuxart; E Ballarín; X Vidal; J Teixidor; J Tomás; M M Villar; J-R Laporte Journal: Eur J Clin Pharmacol Date: 2012-04-15 Impact factor: 2.953
Authors: Erin S LeBlanc; Teresa A Hillier; Kathryn L Pedula; Joanne H Rizzo; Peggy M Cawthon; Howard A Fink; Jane A Cauley; Douglas C Bauer; Dennis M Black; Steven R Cummings; Warren S Browner Journal: Arch Intern Med Date: 2011-09-26
Authors: Jeffry S Nyman; Jesse L Even; Chan-Hee Jo; Erik G Herbert; Matthew R Murry; Gael E Cockrell; Elizabeth C Wahl; R Clay Bunn; Charles K Lumpkin; John L Fowlkes; Kathryn M Thrailkill Journal: Bone Date: 2010-12-23 Impact factor: 4.398
Authors: Christopher Richard D'Adamo; William G Hawkes; Ram Ron Miller; Mark Jones; Marc Hochberg; Janet Yu-Yahiro; J Richard Hebel; Jay Magaziner Journal: Age Ageing Date: 2013-12-25 Impact factor: 10.668
Authors: Ryan P Farmer; Benoit Herbert; Derly O Cuellar; Jiandong Hao; Philip F Stahel; Robin Yasui; David J Hak; Cyril Mauffrey Journal: Int Orthop Date: 2014-03-21 Impact factor: 3.075
Authors: M Neale Weitzmann; Susanne Roser-Page; Tatyana Vikulina; Daiana Weiss; Li Hao; W Hunter Baldwin; Kanglun Yu; Natalia Del Mazo Arbona; Meghan E McGee-Lawrence; Shannon L Meeks; Christine L Kempton Journal: Blood Adv Date: 2019-02-12